AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- U.S. health authorities have turned to a little-known British company to speed development of its first batch of modern vaccines for smallpox, a fatal virus far more infectious than anthrax.
Acambis PLC seems a somewhat unlikely partner for the U.S. Health Department at such a critical moment. It has lost money each year since its founding in
1993, and it has just 150 employees, two-thirds of them at a subsidiary in Cambridge, Massachusetts.
"They've been lucky that they've been in the right place at the right time," said Richard Parkes, a biotechnology analyst at investment bank ING Barings.
Acambis won a $343 million contract in September 2000 to develop a smallpox vaccine for the U.S. Centers for Disease Control and Prevention (CDC). After the September 11 terror attacks, the CDC boosted its order from 40 million doses to 54 million and urged Acambis to hasten development of the new vaccine.
The company now expects to have its first doses ready by 2002, two years earlier than originally planned.
Health and Human Services Secretary Tommy Thompson has asked Congress for $1.6 billion to fight bioterrorism, almost a third of which would pay for an additional 300 million doses of smallpox vaccine - enough to inoculate every American against the disease, which hasn't appeared in the United States since 1949.
Source: HighBeam Research, UK Firm Spearheads Manufacture Of Modern Vaccine.(Brief Article)